IQVIA Holdings ( (IQV) ) has released its Q2 earnings. Here is a breakdown of the information IQVIA Holdings presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IQVIA Holdings Inc. is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries, leveraging advanced analytics and AI-driven solutions to improve patient outcomes worldwide.
In its second-quarter 2025 earnings report, IQVIA Holdings Inc. reported a revenue of $4,017 million, marking a 5.3% increase year-over-year. The company also highlighted a strong performance in its Technology & Analytics Solutions segment, with significant growth in revenue and strategic bookings.
Key financial metrics from the report include a GAAP net income of $266 million and an adjusted EBITDA of $910 million. The company’s R&D Solutions segment saw quarterly bookings of $2.5 billion, contributing to a contracted backlog of $32.1 billion. Additionally, IQVIA repurchased $607 million of common stock during the quarter, exceeding $1 billion in repurchases year-to-date.
IQVIA’s management expressed confidence in the company’s strategic direction, noting improvements in forward-looking demand indicators and a resilient global portfolio. The company updated its full-year 2025 guidance, projecting revenue between $16,100 million and $16,300 million, with adjusted EBITDA expected to range from $3,750 million to $3,825 million.
Looking ahead, IQVIA remains focused on executing its strategic and financial objectives, with expectations of continued growth driven by its diversified offerings and robust demand in the healthcare and life sciences sectors.